公开(公告)号：US20160030506A1

公开(公告)日：2016-02-04

申请号：US14772538

申请日：2014-03-20

Applicant: Yanmin HU ,  HELPERBY THERAPEUTICS LIMITED

Inventor： Yanmin HU ,  Anthony COATES

IPC: A61K38/12 ,  A61K31/7072

CPC classification number: A61K38/12 ,  A61K31/7072 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  A61K2300/00

Abstract: The present invention relates to the use of a combination of an anti-retroviral agent such as zidovudine and an anti-microbial agent for killing clinically latent microorganisms associated with microbial infections and to novel combinations comprising an anti-retroviral agent such as zidovudine and an anti-microbial agent for the treatment of microbial infections.

Abstract translation: 本发明涉及抗逆转录病毒药物如齐多夫定和抗微生物剂的组合用于杀死与微生物感染相关的临床潜在微生物的组合，以及包含抗逆转录病毒药物如齐多夫定和抗 - 微生物剂用于治疗微生物感染。

公开(公告)号：US20190321441A1

公开(公告)日：2019-10-24

申请号：US16405011

申请日：2019-05-07

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K38/12 ,  A61K31/145 ,  A61K31/135 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/405 ,  A61K31/416 ,  A61K31/5415 ,  A61K31/428 ,  A61K31/05 ,  A61K31/382 ,  A61K31/616

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20190111067A1

公开(公告)日：2019-04-18

申请号：US15537119

申请日：2015-12-18

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K31/7036 ,  A61K31/05 ,  A61K31/12 ,  A61K31/4525 ,  A61P31/04 ,  A61K36/9068

Abstract: The present invention relates to the use of one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The present invention also relates to novel combinations comprising one or more compounds selected from the following: carvacrol, thymol, curcumin and piperidine, in combination with an aminoglycoside, for use in the treatment of microbial infections.

公开(公告)号：US20190321384A1

公开(公告)日：2019-10-24

申请号：US16317512

申请日：2017-07-11

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K31/7072 ,  A61K31/407 ,  A61K38/12 ,  A61P31/04

Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof, optionally with a polymyxin selected from polymyxin E and polymyxin or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

公开(公告)号：US20160038438A1

公开(公告)日：2016-02-11

申请号：US14782096

申请日：2014-05-02

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K31/05 ,  A61K31/7036

CPC classification number: A61K31/05 ,  A61K31/7036 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  A61K2300/00

Abstract: The present invention relates to the use of a combination of nordihydroguaiaretic acid and an aminoglycoside for treating a microbial infection or for killing clinically latent microorganisms associated with microbial infections.

Abstract translation: 本发明涉及去甲二氢愈创木酸和氨基糖苷的组合用于治疗微生物感染或杀死与微生物感染相关的临床潜在微生物的用途。

公开(公告)号：US20200000742A1

公开(公告)日：2020-01-02

申请号：US16334002

申请日：2017-10-05

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K31/055 ,  A61K31/382 ,  A61K31/5415 ,  A61K31/197 ,  A61K31/407 ,  A61P31/04

Abstract: The invention provides a combination comprising at least one compound selected from dichlorophen, chlorprothixene, perphenazine, thioridazine, trifluoperazine and edetate or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

公开(公告)号：US20190328832A1

公开(公告)日：2019-10-31

申请号：US16334003

申请日：2017-09-18

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K38/12 ,  A61K31/549 ,  A61K31/5415 ,  A61K31/437 ,  A61K31/166 ,  A61K31/135 ,  A61K31/4535 ,  A61P31/04

Abstract: The invention provides a combination comprising at least one compound selected from metergoline, proglumide, sertraline, hydroflumethiazide, perphenazine, fluphenazine and pimethixene, or a pharmaceutically acceptable derivative thereof, and a polymyxin selected from polymyxin B and colistin, or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.

公开(公告)号：US20180214440A1

公开(公告)日：2018-08-02

申请号：US15565584

申请日：2016-04-11

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU ,  Sanju DHAWAN ,  Kartik SHAH

IPC: A61K31/4745 ,  A61Q11/00 ,  A61K8/43 ,  A61K8/49 ,  A61K8/27 ,  A61K8/36 ,  A61K31/155 ,  A61K33/30 ,  A61K9/00 ,  A61P31/04

CPC classification number: A61K31/4745 ,  A61K8/27 ,  A61K8/36 ,  A61K8/43 ,  A61K8/4926 ,  A61K9/006 ,  A61K9/08 ,  A61K31/155 ,  A61K33/30 ,  A61P31/04 ,  A61Q11/00 ,  A61Q17/005 ,  A61K2300/00

Abstract: The invention provides an oral composition comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof and chlorhexidine or a pharmaceutically acceptable salt and/or solvate thereof, wherein the composition is in the form of a mouthwash and comprises about 0.001% w/v to about 0.06% w/v of chlorhexidine or a pharmaceutically acceptable salt and/or solvate thereof. Also provided is an oral composition comprising 4-methyl-8-phenoxy-1-(2-phenylethyl)-2,3-dihydro-1H-pyrrolo[3,2-c]quinoline or a pharmaceutically acceptable salt and/or solvate thereof, chlorhexidine or a pharmaceutically acceptable salt and/or solvate thereof, and a zinc compound.

公开(公告)号：US20170348383A1

公开(公告)日：2017-12-07

申请号：US15537007

申请日：2015-12-18

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Anthony COATES ,  Yanmin HU

IPC: A61K38/12 ,  A61K31/5415 ,  A61K31/428 ,  A61K31/416 ,  A61K31/405 ,  A61K31/382 ,  A61K31/196 ,  A61K31/192 ,  A61K31/145 ,  A61K31/616 ,  A61K31/05

CPC classification number: A61K38/12 ,  A61K31/05 ,  A61K31/135 ,  A61K31/145 ,  A61K31/192 ,  A61K31/196 ,  A61K31/216 ,  A61K31/382 ,  A61K31/405 ,  A61K31/416 ,  A61K31/428 ,  A61K31/5415 ,  A61K31/616 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483 ,  A61K2300/00

Abstract: The present invention relates to the use of one or more compounds selected from the following: caffeic acid, thymol, aspirin, benzydamine hydrochloride, diclofenac sodium, flurbiprofen, ibuprofen, indomethacin, trifluoperazine hydrochloride, chlorprothixene hydrochloride, triflupromazine hydrochloride, suloctidil, thioridazine hydrochloride, dichlorophen, saccharin and piroxicam, in combination with a polymyxin selected from colistin or polymyxin B or a pharmaceutically acceptable derivative thereof, for use in the treatment of a microbial infection, and in particular for killing clinically latent microorganisms associated with microbial infections. The invention also provides a combination comprising suloctidil or a pharmaceutically acceptable derivative or prodrug thereof, and a polymyxin selected from polymyxin E and polymyxin B or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment and/or prevention of microbial infections.

公开(公告)号：US20170258784A1

公开(公告)日：2017-09-14

申请号：US15608032

申请日：2017-05-30

Applicant: HELPERBY THERAPEUTICS LIMITED

Inventor： Petra Helga BECK ,  Marc Barry BROWN ,  David Edward CLARK ,  Anthony COATES ,  Hazel Joan DYKE ,  Yanmin HU ,  Derek John LONDESBROUGH ,  Keith MILLS ,  Thomas David PALLIN ,  Gary Patrick REID ,  Gerlinda STODDART

IPC: A61K31/4709 ,  A61L2/00 ,  A61K31/4439

CPC classification number: A61K31/4745 ,  A01N43/90 ,  A61K31/43 ,  A61K31/4439 ,  A61K31/4706 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/496 ,  A61K31/497 ,  A61K31/546 ,  A61K31/7052 ,  A61L2/0088 ,  C07D471/04 ,  Y02A50/401 ,  Y02A50/404 ,  Y02A50/406 ,  Y02A50/411 ,  Y02A50/469 ,  Y02A50/473 ,  Y02A50/475 ,  Y02A50/478 ,  Y02A50/479 ,  Y02A50/481 ,  Y02A50/483

Abstract: There is provided the use of compounds of formula I wherein R1, R2, R3 and X have meanings given in the description, for the preparation of a medicament for killing clinically latent microorganisms. There is also provided the use of compounds of formula I for treating microbial infections, as well as certain compounds of formula I per se.